Second rejection for tumor destroyer puts Replimune on a ‘challenging path’
Replimune’s CEO Sushil Patel has already warned that the biotech will need to cut staff and substantially scale back its U.S. manufacturing operations.
Second rejection for tumor destroyer puts Replimune on a ‘challenging path’ Read More »
